Joel Scherer

Joel Scherer has worked in the pharmaceutical industry for many years. Joel began their career at Eli Lilly and Company in 2008, where they served as Managing Director and Chief Medical Officer of Chorus. In 2014, they founded and became President of Kouros Pharmaceutical Consulting. LLC, providing pharmaceutical development and strategic consulting services. In 2016, they were appointed Chair of the Antibody Scientific Advisory Board at the Tri-Institutional Therapeutic Discovery Institute. In 2017, they joined Boston Pharmaceuticals as Entrepreneur-in-Residence and Interim Chief Medical Officer, and also joined Bridge Medicines as a Member of the Scientific Advisory Board. In 2019, they became Chief Medical Officer at Atlas Venture start-up (TBA). In 2020, they were appointed Interim Chief Medical Officer at Q32 Bio Inc. and in 2022 they were appointed Vice President of Clinical Development, Immunotherapeutics at Q32 Bio Inc.

Joel Scherer received their Bachelor of Science (BS) in Chemistry from the University of Wisconsin-Madison in 1973. Joel then went on to pursue a Masters Degree in Organic Chemistry from Harvard University, which they completed in 1976. Finally, they obtained their Doctor of Medicine (MD) from Stanford University School of Medicine in 1981.